Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 10, 2005, Pages 1001-1006

  Riksen, Niels P ^a   Rongen, Gerard A ^a   Blom, Henk J ^a   Boers, Godfried H J ^a   Smits, Paul ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenosine; Cardiovascular disease; Dipyridamole; Hyperhomocysteinemia

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSYLHOMOCYSTEINASE; DIPYRIDAMOLE; HOMOCYSTEINE; PURINE NUCLEOSIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATALYSIS; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; EQUILIBRIUM CONSTANT; EXTRACELLULAR SPACE; HEART PROTECTION; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; NONHUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADENOSINE; ANIMALS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RECEPTORS, PURINERGIC P1;

ANIMALIA;

EID: 27744595306     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.175     Document Type: Review

References (46)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015-22.
2. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
3. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Vale D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001:2007-56.
4. Mudd SH, Skovby F, Levy HL, Pettigrew KID, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985:37:1-31.
5. Zylberstein DE, Bengtsson C, Bjorkelund C, Landaas S, Sundh V, Thelle D, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004;109:601-6.
6. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. J Am Med Assoc 2003;289:1251-7.
7. Riksen NP, Rongen GA, Blom HJ, Russel FG, Boers GH, Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003;59:271-6.
8. Riksen NP, Rongen GA, Boers GH, Blom HJ, van den Broek PH, Smits P. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2005;25:109-14.
9. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002;106:1275-81.
10. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. J Am Med Assoc 1999;281:2113-8.
11. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
12. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engi J Med 1998;338:1042-50.
13. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003;23:418-24.
14. Blom HJ, van der Molen EF. Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1994;8(Suppl 2):86-7.
15. Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380-5.
16. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 2001;88:1203-9.
17. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-23.
18. Ueland PM. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev 1982;34:223-53.
19. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001;74:723-9.
20. Finkelstein JD. The metabolism of homoceysteine: pathways and regulation. Eur J Pediatr 1998;157(Suppi 2):S40-S44.
21. Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost 2000;26:227-32.
22. van der Molen EF, Hiipakka MJ, Lith-Zanders H, Boers GH, van den Heuvel LP, Monnens LA, et al. Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine beta-synthase (CS) deficiency. Thromb Haemost 1997;78:827-33.
23. Achterberg PW, de Tombe PP, Harmsen E, de Jong JW. Myocardial S-adenosylhomocysteine hydrolase is important for adenosine production during normoxia. Biochim Biophys Acta 1985;840:393-400.
24. Kloor D, Delabar U, Muhlbauer B, Luippold G, Osswald H. Tissue levels of S-adenosylhomocysteine in the rat kidney: effects of ischemia and homocysteine. Biochem Pharmacol 2002;63:809-15.
25. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-25.
26. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch Pharmacol 2000;362:351-63.
27. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25:33-9.
28. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
29. Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Frog Cardiovasc Dis 1989;32:73-97.
30. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterization to clinical application. Part I. Neth J Med 2004;62:353-63.
31. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001;91:133-147.
32. Jackson EK. Adenosine: a physiological brake on renin release.Annu Rev Pharmacol Toxicol 1991;31:1-35.
33. Rongen GA, Lenders JW, Lambrou J, Willemsen JJ, Van Belle H, Thien T, et al. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension 1996;27:933-8.
34. Smits P, Lenders JW, Willemsen JJ, Thien T. Adenosine attenuates the response to sympathetic stimuli in humans. Hypertension 1991;18:216-23.
35. Edlund A, Siden A, Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res 1987;45:183-90.
36. Minamino T, Kitakaze M, Asanuma H, Tomiyama Y, Shiraga M, Sato H, et al. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest 1998;101:1643-53.
37. Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998;91:57-64.
38. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002;22:364-73.
39. Peyot ML, Gadeau AP, Dandre F, Belloc I, Dupuch F, Desgranges C. Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor. Circ Res 2000;86:76-85.
40. Dubey RK, Gillespie DG, Jackson EK. A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension 2002;39:530-5.
41. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85:893-904.
42. Schrader J, Schutz W, Bardenheuer H. Role of S-adenosylhomocysteine hydrolase in adenosine metabolism in mammalian heart. Biochem J 1981;196:65-70.
43. Deussen A, Borst M, Schrader J. Formation of S-adenosylhomocysteine in the heart. I: an index of free intracellular adenosine. Circ Res 1988;63:240-9.
44. Sciotti VM, Van Wylen DG. Attenuation of ischemia-induced extracellular adenosine accumulation by homocysteine. J Cereb Blood Flow Metab 1993;13:208-13.
45. Reddington M, Pusch R. Adenosine metabolism in a rat hippocampal slice preparation: incorporation into S-adenosylhomocysteine. J Neurochem 1983;40:285-90.
46. Henrichs KJ, Matsuoka H, Schaper W. Intracellular trapping of adenosine during myocardial ischemia by L-homocysteine. Basic Res Cardiol 1986;81:267-75.